Z89.421
✓ BillableAcquired absence of other right toe(s)
Factors influencing health status and contact with health services (Z00-Z99)
❌ Excludes1
inheritedRules inherited from parent codes in the hierarchy.
- • acquired deformities of limbs (M20-M21)
- • congenital absence of limbs (Q71-Q73)
⚠️ Excludes2
inheritedRules inherited from parent codes.
- • acquired absence of great toe (Z89.41-)
Clinical Description
ICD-10-CM code Z89.421 represents acquired absence of other right toe(s). This code falls under the Factors influencing health status and contact with health services (Z00-Z99) classification. It is a billable/specific code valid for HIPAA-covered transactions as of October 1, 2025 (FY2026). This code can be used to indicate a diagnosis for reimbursement purposes on insurance claims.
This is a 7-character code at the 6th level of specificity. This is the most specific code available in this subcategory. Coders should note that Z89.421 has 2 Excludes1 restriction(s) — codes that cannot be reported together on the same claim.
Frequently Asked Questions
What is ICD-10 code Z89.421?
ICD-10-CM code Z89.421 is "Acquired absence of other right toe(s)". It belongs to the category: Factors influencing health status and contact with health services (Z00-Z99).
Is Z89.421 a billable ICD-10 code?
Yes, Z89.421 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
What codes are excluded with Z89.421?
Z89.421 has 2 Excludes1 rule(s). These codes are mutually exclusive and cannot be coded together on the same claim.
Can Z89.421 be coded with other codes?
Z89.421 has 1 Excludes2 note(s). These conditions can be coded together if both are documented in the patient record.
Related Codes in Z89.42
Other codes in the same category that may be relevant for differential coding:
🧪 Validate Combinations
Add Z89.421 to the Excludes Checker to validate against your full code list.
Open in Checker →Code Information
Data Source
CMS ICD-10-CM 2026 Tabular List
Updated October 1, 2025 (FY2026)